Abstract
The most efficient approach for relief of the vasomotor symptoms of the menopause at any age comprises MHT based on estrogens (alone or in combination with progestogens), tibolone, and the combination of conjugated estrogens and bazedoxifene. Randomized placebo-controlled trials have demonstrated that low-dose vaginal estrogen, intravaginal dehydroepiandrosterone, and oral ospemifene effectively improve vaginal comfort and trophism. Findings from randomized clinical trials, as well as preclinical, clinical, and epidemiologic studies, clarify the favorable benefit-risk profile for MHT use by recently menopausal women (also known as the timing hypothesis) with bothersome vasomotor and related menopausal symptoms. The window-of-opportunity theory has been extended to other putative benefits of hormone therapy, including reducing dementia, improving cognition, and preventing mood disorders. However, supporting evidence is limited. We must emphasize the individualization and shared decision-making that facilitates the appropriate decisions regarding the use of MHT.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- AD:
-
Alzheimer’s disease
- BC:
-
Breast cancer
- BMD:
-
Bone mineral density
- CE/BZA:
-
Combination of conjugated estrogens and bazedoxifene
- CHD:
-
Coronary heart disease
- CVD:
-
Cardiovascular disease
- E2:
-
Estradiol
- E4:
-
Estetrol
- E-MHT:
-
Unopposed estrogen therapy
- EP-MHT:
-
Combined therapy of estrogen and progestogen
- ER:
-
Estrogen receptor
- FSFI:
-
Female Sexual Function Index
- HR:
-
Hazard ratio
- HSDD:
-
Hypoactive sexual desire disorder
- KEEPS:
-
Kronos Early Estrogen Prevention Study
- LMP:
-
Last menstrual period
- LNG-IUS:
-
Levonorgestrel-releasing intrauterine system
- MHT:
-
Menopausal hormone therapy
- P4:
-
Natural progesterone
- POP:
-
Pelvic organ prolapse
- QoL:
-
Quality of life
- RCT:
-
Randomized controlled trial
- ROS:
-
Reactive oxygen species
- SERM:
-
Selective estrogen receptor modulator
- TSEC:
-
Tissue-selective estrogen complex
- VMS:
-
Vasomotor symptoms
- VTE:
-
Venous thromboembolism
References
US Preventive Services Task Force, Grossman DC, Curry SJ, Owens DK, Barry MJ, Davidson KW, Doubeni CA, Epling JW Jr, Kemper AR, Krist AH, Kurth AE, Landefeld CS, Mangione CM, Phipps MG, Silverstein M, Simon MA, Tseng CW. Hormone therapy for the primary prevention of chronic conditions in postmenopausal women: US preventive services task force recommendation statement. JAMA. 2017;318(22):2224–33.
Marjoribanks J, Farquhar C, Roberts H, Lethaby A, Lee J. Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev. 2017;(1):CD004143.
Cano A, Rees M, Simoncini T. Comments on the USPSTF draft recommendation statement on menopausal hormone therapy: primary prevention of chronic conditions. Maturitas. 2018;107:A1–2.
Manson JE, Kaunitz A. Menopause management: getting clinical care back on track. N Engl J Med. 2019;374:803–6.
Taylor HS, Manson JE. Update in hormone therapy use in menopause. J Clin Endocrinol Metab. 2011;96(2):255–64.
Choi DS, Lee DY, Yoon BK. Effects of transdermal estrogen gel in postmenopausal Korean women. J Korean Soc Menopause. 2012;18:113–8.
Naunton M, Al Hadithy AF, Brouwers JR, Archer DF. Estradiol gel: review of the pharmacology, pharmacokinetics, efficacy, and safety in menopausal women. Menopause. 2006;13(3):517–27.
Gompel A. Progesterone, progestins and the endometrium in perimenopause and in menopausal hormone therapy. Climacteric. 2018;21(4):321–5.
Furness S, Roberts H, Marjoribanks J, Lethaby A. Hormone therapy in postmenopausal women and risk of endometrial hyperplasia. Cochrane Database Syst Rev. 2012;(8):CD000402.
Mirkin S. Evidence on the use of progesterone in menopausal hormone therapy. Climacteric. 2018;21(4):346–54.
Depypere H, Inki P. The levonorgestrel-releasing intrauterine system for endometrial protection during estrogen replacement therapy: a clinical review. Climacteric. 2015;18(4):470–82.
Faubion SS, Kaunitz AM. Stopping systemic menopausal hormone therapy: why, when and how. Maturitas. 2016;89:3–4.
Sánchez-Borrego R, Llaneza P, Mendoza N, Comino R, Ferrer J, Baquedano L, Jurado AR, Manubens M, Otero B, Lubián D, Coronado P, Cancelo MJ, Calaf J, Palacios S. AEEM-SEGO position statement on menopausal hormone therapy. Progr Obstet Gynecol. 2018;61(3):232–6.
Pinkerton JV. What are the concerns about custom-compounded “bioidentical” hormone therapy? Menopause. 2014;21(12):1298–300.
Mendoza N, Juliá MD, Galliano D, Coronado P, Díaz B, Fontes J, Gallo JL, García A, Guinot M, Munnamy M, Roca B, Sosa M, Tomás J, Llaneza P, Sánchez-Borrego R. Spanish consensus on premature menopause. Maturitas. 2015;80(2):220–5.
Maclennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev. 2004;(4):CD002978.
Mendoza N, Abad P, Baró F, Cancelo MJ, Llaneza P, Manubens M, Quereda F, Sánchez-Borrego R. Spanish menopause society position statement: use of tibolone in postmenopausal women. Menopause. 2013;20(7):754–60.
Formoso G, Perrone E, Maltoni S, Balduzzi S, D’Amico R, Bassi C, Basevi V, Marata AM, Magrini N, Maestri E. Short and long term effects of tibolone in postmenopausal women. Cochrane Database Syst Rev. 2012;(2):CD008536.
Pickar JH, Boucher M, Morgenstern D. Tissue selective estrogen complex (TSEC): a review. Menopause. 2018;25(9):1033–45.
Llaneza P, Calaf J, Jurado AR, Mendoza N, Otero B, Quereda F, Sánchez-Borrego R, Lubian D. What do TSECs provide in the menopausal hormone therapy? Gynecol Endocrinol. 2018;34:826–32.
Baquedano L, Sánchez-Borrego R, Abad P, Jurado AR, Manubens M, Mendoza N. Innovative treatment in menopause: tissue-selective estrogen complex (TSEC). Reprod Med Int. 2018;1(1):1–5.
de Villiers TJ, Hall JE, Pinkerton JV, Cerdas Pérez S, Rees M, Yang C, Pierroz DD. Revised global consensus statement on menopausal hormone therapy. Climacteric. 2016;19(4):313–5.
Cintron D, Lahr BD, Bailey KR, Santoro N, Lloyd R, Manson JE, Neal-Perry G, Pal L, Taylor HS, Wharton W, Naftolin F, Harman SM, Miller VM. Effects of oral versus transdermal menopausal hormone treatments on self-reported sleep domains and their association with vasomotor symptoms in recently menopausal women enrolled in the Kronos early Estrogen prevention study (KEEPS). Menopause. 2018;25(2):145–53.
Joffe H, Petrillo LF, Koukopoulos A, et al. Increased estradiol and improved sleep, but not hot flashes, predict enhanced mood during the menopausal transition. J Clin Endocrinol Metab. 2011;96(7):E1044–54.
Soares CN, Arsenio H, Joffe H, et al. Escitalopram versus ethinyl estradiol and norethindrone acetate for symptomatic peri- and postmenopausal women: impact on depression, vasomotor symptoms, sleep, and quality of life. Menopause. 2006;13(5):780–6.
Gleason CE, Dowling NM, Wharton W, et al. Effects of hormone therapy on cognition and mood in recently postmenopausal women: findings from the randomized, controlled KEEPS-cognitive and affective study. PLoS Med. 2015;12(6):e1001833.
Gordon JL, Rubinow DR, Eisenlohr-Moul TA, Xia K, Schmidt PJ, Girdler SS. Efficacy of transdermal Estradiol and micronized progesterone in the prevention of depressive symptoms in the menopause transition: a randomized clinical trial. JAMA Psychiat. 2018;75(2):149–57.
Barnabei VM, Cochrane BB, Aragaki AK, Nygaard I, Williams RS, McGovern PG, Young RL, Wells EC, O’Sullivan MJ, Chen B, Schenken R, Johnson SR, Women’s Health Initiative Investigators. Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women’s Health Initiative. Obstet Gynecol. 2005;105(5 Pt 1):1063.
Chlebowski RT, Cirillo DJ, Eaton CB, Stefanick ML, Pettinger M, Carbone LD, Johnson KC, Simon MS, Woods NF, Wactawski-Wende J. Estrogen alone and joint symptoms in the Women’s Health Initiative randomized trial. Menopause. 2013;20(6):600.
Xiao YP, Tian FM, Dai MW, Wang WY, Shao LT, Zhang L. Are estrogen-related drugs new alternatives for the management of osteoarthritis? Arthritis Res Ther. 2016;18:151.
Komm BS, Vlasseros F, Samadfam R, Chouinard L, Smith SY. Skeletal effects of bazedoxifene paired with conjugated estrogens in ovariectomized rats. Bone. 2011;49:376–86.
Taylor HS, Tal A, Pal L, et al. Effects of oral vs transdermal estrogen therapy on sexual function in early post menopause: ancillary study of the Kronos early estrogen prevention study (KEEPS). JAMA Intern Med. 2017;177(10):1471–9.
Nastri CO, Lara LA, Ferriani RA, Rosa-E-Silva AC, Figueiredo JB, Martins WP. Hormone therapy for sexual function in perimenopausal and postmenopausal women. Cochrane Database Syst Rev. 2013;(6):CD009672.
Pitsouni E, Grigoriadis T, Douskos A, Kyriakidou M, Falagas ME, Athanasiou S. Efficacy of vaginal therapies alternative to vaginal estrogens on sexual function and orgasm of menopausal women: a systematic review and meta-analysis of randomized controlled trials. Eur J Obstet Gynecol Reprod Biol. 2018;229:45–56.
Sánchez-Borrego R, Manubens M, Navarro MC, Cancelo MJ, Beltrán E, Duran M, Orte T, Baquedano L, Palacios S, Mendoza N, Spanish Menopause Society. Position of the Spanish menopause society regarding vaginal health care in postmenopausal women. Maturitas. 2014;78(2):146–50.
Portman DJ, Gass ML, Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and the North American Menopause Society. Menopause. 2014;21:1063–8.
Robinson D, Toozs-Hobson P, Cardozo L. The effect of hormones on the lower urinary tract. Menopause Int. 2013;19(4):155–62.
Nappi RE, Davis SR. The use of hormone therapy for the maintenance of urogynecological and sexual health post WHI. Climacteric. 2012;15(3):267–74.
Lethaby A, Ayeleke RO, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2016;(8):CD001500.
Del Pup L, Di Francia R, Cavaliere C, Facchini G, Giorda G, De Paoli P, Berretta M. Promestriene, a specific topic estrogen. Review of 40 years of vaginal atrophy treatment: is it safe even in cancer patients? Anti-Cancer Drugs. 2013;24(10):989–98.
Simon J, Portman D, Mabey RG Jr, Ospemifene Study Group. Long-term safety of ospemifene (52-week extension) in the treatment of vulvar and vaginal atrophy in hysterectomized postmenopausal women. Maturitas. 2014;77(3):274–81.
Simon JA, Goldstein I, Kim NN, Davis SR, Kellogg-Spadt S, Lowenstein L, Pinkerton JV, Stuenkel CA, Traish AM, Archer DF, Bachmann G, Goldstein AT, Nappi RE, Vignozzi L. The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): International Society for the Study of Women’s Sexual Health (ISSWSH) expert consensus panel review. Menopause. 2018;25(7):837–47.
Davis SR, Worsley R, Miller KK, Parish SJ, Santoro N. Androgens and female sexual function and dysfunction—findings from the fourth international consultation of sexual medicine. J Sex Med. 2016;13:168–78.
Simon J, Braunstein G, Nachtigall L, Utian W, Katz M, Miller S, Waldbaum A, Bouchard C, Derzko C, Buch A, Rodenberg C, Lucas J, Davis S. Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J Clin Endocrinol Metab. 2005;90(9):5226–33.
Shifren JL, Davis SR, Moreau M, Waldbaum A, Bouchard C, DeRogatis L, Derzko C, Bearnson P, Kakos N, O’Neill S, Levine S, Wekselman K, Buch A, Rodenberg C, Kroll R. Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM1 study. Menopause. 2006;13(5):770–9.
Nachtigall L, Casson P, Lucas J, Schofield V, Melson C, Simon JA. Safety and tolerability of testosterone patch therapy for up to 4 years in surgically menopausal women receiving oral or transdermal oestrogen. Gynecol Endocrinol. 2011;27:39–48.
Labrie F, Archer DF, Koltun W, Vachon A, Young D, Frenette L, Portman D, Montesino M, Côté I, Parent J, Lavoie L, Beauregard A, Martel C, Vaillancourt M, Balser J, Moyneur É, VVA Prasterone Research Group. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause. 2016;23(3):243–56.
Labrie F, Derogatis L, Archer DF, Koltun W, Vachon A, Young D, Frenette L, Portman D, Montesino M, Côté I, Parent J, Lavoie L, Beauregard A, Martel C, Vaillancourt M, Balser J, Moyneur É, Members of the VVA Prasterone Research Group. Effect of intravaginal prasterone on sexual dysfunction in postmenopausal women with vulvovaginal atrophy. J Sex Med. 2015;12(12):2401–12.
Bouchard C, Labrie F, Derogatis L, Girard G, Ayotte N, Gallagher J, Cusan L, Archer DF, Portman D, Lavoie L, Beauregard A, Côté I, Martel C, Vaillancourt M, Balser J, Moyneur E, VVA Prasterone Group. Effect of intravaginal dehydroepiandrosterone (DHEA) on the female sexual function in postmenopausal women: ERC-230 open-label study. Horm Mol Biol Clin Investig. 2016;25(3):181–90.
Constantine G, Graham S, Portman DJ, Rosen RC, Kingsberg SA. Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial. Climacteric. 2015;18(2):226–32.
Stamm WE. Estrogens and urinary-tract infection. J Infect Dis. 2007;195(5):623.
Pérez-López FR, Cuadros JL, Fernández-Alonso AM, Chedraui P, Sánchez-Borrego R, Monterrosa A. Urinary incontinence, related factors and menopause-related quality of life in mid-aged women assessed with the Cervantes scale. Maturitas. 2012;73(4):369–72.
Cody JD, Jacobs ML, Richardson K, Moehrer B, Hextall A. Oestrogen therapy for urinary incontinence in post-menopausal women. Cochrane Database Syst Rev. 2012;(10):CD001405.
Giannini A, Russo E, Cano A, Chedraui P, Goulis DG, Lambrinoudaki I, Lopes P, Mishra G, Mueck A, Rees M, Senturk LM, Stevenson JC, Stute P, Tuomikoski P, Simoncini T. Current management of pelvic organ prolapse in aging women: EMAS clinical guide. Maturitas. 2018;110:118–23.
Fuermetz A, Schoenfeld M, Ennemoser S, Muetzel E, Jeschke U, Jundt K. Change of steroid receptor expression in the posterior vaginal wall after local estrogen therapy. Eur J Obstet Gynecol Reprod Biol. 2015;187:45–50.
Ismail SI, Bain C, Hagen S. Oestrogens for treatment or prevention of pelvic organ prolapse in postmenopausal women. Cochrane Database Syst Rev. 2010;(9):CD007063.
Rahn DD, Good MM, Roshanravan SM, Shi H, Schaffer JI, Singh RJ, et al. Effects of preoperative local estrogen in postmenopausal women with prolapse: a randomized trial. J Clin Endocrinol Metab. 2014;99:3728–36.
Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297:1465.
Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291:1701.
Clarkson TB, Meléndez GC, Appt SE. Timing hypothesis for postmenopausal hormone therapy: its origin, current status, and future. Menopause. 2013;20(3):342–53.
Usselman CW, Stachenfeld NS, Bender JR. The molecular actions of oestrogen in the regulation of vascular health. Exp Physiol. 2016;101(3):356–61.
Hodis HN, Mack WJ. The timing hypothesis and hormone replacement therapy: a paradigm shift in the primary prevention of coronary heart disease in women. 1. Comparison of therapeutic efficacy. J Am Geriatr Soc. 2013;61:1005–10.
Hodis HN, Mack WJ. The timing hypothesis and hormone replacement therapy: a paradigm shift in the primary prevention of coronary heart disease in women. 2. Comparative risks. J Am Geriatr Soc. 2013;61:1011–8.
Hodis HN, Mack WJ, Henderson VW, et al.; for the ELITE Research Group. Vascular effects of early versus late postmenopausal treatment with estradiol. N Engl J Med. 2016;374(13):1221–1231.
Harman SM, Black DM, Naftolin F, Brinton EA, Budoff MJ, Cedars MI, Hopkins PN, Lobo RA, Manson JE, Merriam GR, Miller VM, Neal-Perry G, Santoro N, Taylor HS, Vittinghoff E, Yan M, Hodis HN. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. Ann Intern Med. 2014;161(4):249–60.
Pines A. KEEPS results: a true frustration? Climacteric. 2015;18(2):110–1.
Canonico M. Hormone therapy and risk of venous thromboembolism among postmenopausal women. Maturitas. 2015;82(3):304–7.
Canonico M, Oger E, Plu-Bureau G, Conard J, Meyer G, Levesque H, Trillot N, Barrellier MT, Wahl D, Emmerich J, Scarabin PY, Estrogen and Thromboembolism Risk Study Group. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation. 2007;115:840–5.
Canonico M, Fournier A, Carcaillon L, Olie V, Plu-Bureau G, Oger E, Mesrine S, Boutron-Ruault MC, Clavel-Chapelon F, Scarabin PY. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arterioscler Thromb Vasc Biol. 2010;30:340–5.
World Health Statistics. Mental health of older adults. 2017. www.who.int/mediacentre/factsheets/fs381/en/.
Luine VN. Estradiol and cognitive function: past, present and future. Horm Behav. 2014;66(4):602–18.
Zárate S, Stevnsner T, Gredilla R. Role of estrogen and other sex hormones in brain aging. Neuroprotection and DNA repair. Front Aging Neurosci. 2017;9:430.
Whitmer RA, Quesenberry CP, Zhou J, Yaffe K. Timing of hormone therapy and dementia: the critical window theory revisited. Ann Neurol. 2011;69(1):163–9.
Henderson VW, St John JA, Hodis HN, McCleary CA, Stanczyk FZ, Shoupe D, Kono N, Dustin L, Allayee H, Mack WJ. Cognitive effects of estradiol after menopause: a randomized trial of the timing hypothesis. Neurology. 2016;87(7):699–708.
Espeland MA, Shumaker SA, Leng I, Manson JE, Brown CM, LeBlanc ES, Vaughan L, Robinson J, Rapp SR, Goveas JS, Wactawski-Wende J, Stefanick ML, Li W, Resnick SM, WHIMSY Study Group. Long-term effects on cognitive function of postmenopausal hormone therapy prescribed to women aged 50 to 55 years. JAMA Intern Med. 2013;173(15):1429–36.
Shao H, Breitner JC, Whitmer RA, Wang J, Hayden K, Wengreen H, Corcoran C, Tschanz J, Norton M, Munger R, Welsh-Bohmer K, Zandi PP, Cache County Investigators. Hormone therapy and Alzheimer disease dementia: new findings from the Cache County study. Neurology. 2012;79(18):1846–52.
Manson JE, Aragaki AK, Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Chlebowski RT, Howard BV, Thomson CA, Margolis KL, Lewis CE, Stefanick ML, Jackson RD, Johnson KC, Martin LW, Shumaker SA, Espeland MA, Wactawski-Wende J, WHI Investigators. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women’s Health Initiative randomized trials. JAMA. 2017;318(10):927–38.
Barros LA, Tufik S, Andersen ML. The role of progesterone in memory: an overview of three decades. Neurosci Biobehav Rev. 2015;49:193–204.
Yoon BK, Kim DK, Kang Y, Kim JW, Shin MH, Na DL. Hormone replacement therapy in women with Alzheimer’s disease: a randomized, prospective study. Fertil Steril. 2003;79:274–80.
Henderson VW. Progesterone and human cognition. Climacteric. 2018;21(4):333–40.
Zandi PP, Carlson MC, Plassman BL, Welsh-Bohmer KA, Mayer LS, Steffens DC, Breitner JC, Cache County Memory Study Investigators. Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County study. JAMA. 2002;288(17):2123–9.
Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J, Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–33.
LaCroix AZ, Chlebowski RT, Manson JE, et al.; WHI Investigators. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA. 2011;305:1305–1314.
Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat. 2008;107:103–11.
Fournier A, Fabre A, Mesrine S, Boutron-Ruault MC, Berrino F, Clavel-Chapelon F. Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer. J Clin Oncol. 2008;26:1260–8.
Lyytinen H, Pukkala E, Ylikorkala O. Breast cancer risk in postmenopausal women using estradiol–progestogen therapy. Obstet Gynecol. 2009;113:65–73.
Fournier A, Mesrine S, Boutron-Ruault MC, Clavel-Chapelon F. Estrogen-progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks? J Clin Oncol. 2009;27:5138–43.
Plotogea MN, Ionescu OM, Bratila E, Comandasu DE, Berceanu C, Mehedintu C. Hormone replacement therapy and the impact of “gap time” in cardiovascular versus breast cancer risk. Maturitas. 2017;100:152.
Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, Hubbell FA, Ascensao J, Rodabough RJ, et al. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med. 2004;350:991–1004.
Lufkin EG, Wahner HW, O’Fallon WM, Hodgson SF, Kotowicz MA, Lane AW, Judd HL, Caplan RH, Riggs BL. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med. 1992;117(1):1–9.
Ishida Y, Kawai S. Comparative efficacy of hormone replacement therapy, etidronate, calcitonin, alfacalcidol, and vitamin K in postmenopausal women with osteoporosis: the Yamaguchi Osteoporosis Prevention Study. Am J Med. 2004;117(8):549–55.
Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, Anderson G, Howard BV, Thomson CA, LaCroix AZ, Wactawski-Wende J, Jackson RD, Limacher M, Margolis KL, Wassertheil-Smoller S, Beresford SA, Cauley JA, Eaton CB, Gass M, Hsia J, et al. The Women’s Health Initiative hormone therapy trials: update and overview of health outcomes during the intervention and post-stopping phases. JAMA. 2013;310(13):1353–68.
Papadakis G, Hans D, González-Rodríguez E, Vollenweider P, Waeber G, Marques-Vidal PM, Lamy O. The benefit of menopausal hormone therapy on bone density and microarchitecture persists after its withdrawal. J Clin Endocrinol Metab. 2016;101(12):5004–11.
Watts NB, Cauley JA, Jackson RD, LaCroix AZ, Lewis CE, Manson JE, Neuner JM, Phillips LS, Stefanick ML, Wactawski-Wende J, Crandall C, Women’s Health Initiative Investigators. No increase in fracture after stopping hormone therapy: results from the Women’s Health Initiative. J Clin Endocrinol Metab. 2017;102(1):302–8.
Tiidus PM. Benefits of estrogen replacement for skeletal muscle mass and function in post-menopausal females: evidence from human and animal studies. Eurasian J Med. 2011;43:109–14.
Calleja-Agius J, Muscat-Baron Y, Brincat MP. Estrogens and the intervertebral disc. Menopause Int. 2009;15:127–30.
Woods GN, Huang M-H, Cawthon PM, McDaniels-Davidson C, Fink HA, Kado DM, Study of Osteoporotic Fractures (SOF) Research Group. Patterns of menopausal hormone therapy use and hyperkyphosis in older women. Menopause. 2018;25(7):738–43.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Sánchez-Borrego, R. (2019). Menopausal Hormone Therapy to Prevent Chronic Conditions. In: Pérez-López, F. (eds) Postmenopausal Diseases and Disorders. Springer, Cham. https://doi.org/10.1007/978-3-030-13936-0_22
Download citation
DOI: https://doi.org/10.1007/978-3-030-13936-0_22
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-13935-3
Online ISBN: 978-3-030-13936-0
eBook Packages: MedicineMedicine (R0)